Related Experiment Video

Updated: May 21, 2026

Seven Steps to Stellate Cells
06:40

Seven Steps to Stellate Cells

Published on: May 10, 2011

Pentoxifylline inhibits hepatic stellate cells proliferation via the Raf/ERK pathway

Di Zhang1, Huiqing Jiang, Yan Wang

  • 1Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang, China.

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|June 22, 2012
PubMed

Insights

Pentoxifylline (PTX) significantly reduces hepatic stellate cell (HSC) proliferation. This effect is mediated by the PTX-induced suppression of the Raf/MEK/extracellular-signal-regulated kinase (ERK) signaling pathway.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Pharmacology

Background:

  • Pentoxifylline (PTX), a xanthine derivative, is known to suppress tumor necrosis factor-alpha (TNF-alpha) production.
  • PTX also inhibits collagen synthesis in hepatic stellate cells (HSCs) in vitro.
  • HSCs play a crucial role in liver fibrogenesis.

Purpose of the Study:

  • To investigate the effects of PTX on HSC proliferation.
  • To elucidate the role of the Raf/MEK/extracellular-signal-regulated kinase (ERK) signaling pathway in PTX-mediated HSC proliferation inhibition.

Main Methods:

  • Utilized rat hepatic stellate cell line T6 and primary activated rat HSCs.
  • Assessed cell proliferation rates and cell cycle distribution (S and G2/M phases) following PTX treatment.
  • Examined the phosphorylation status of Raf-1 and ERK in response to PTX.

Main Results:

  • PTX treatment significantly decreased HSC proliferation in both T6 and primary cells.
  • PTX reduced the HSC population in the S and G2/M phases of the cell cycle.
  • PTX inhibited the phosphorylation of Raf-1 (p-Raf-1) and ERK (p-ERK) in a dose- and time-dependent manner.
  • Inhibitors of Raf-1 and ERK mimicked the anti-proliferative effects of PTX.

Conclusions:

  • PTX effectively suppresses HSC proliferation.
  • The Raf/MEK/ERK signaling pathway is a key mediator of PTX's anti-proliferative effects on HSCs.
  • PTX demonstrates potential as a therapeutic agent for liver diseases characterized by HSC activation and proliferation.

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...